Marc Gruninger
Director · Veraxa Biotech AG - Post de-SPAC
- 2026
- Oct 29, 2026
- 1
Summary
Latest filing:
Marc Gruninger is Director of Veraxa Biotech AG - Post de-SPAC (VRXA). 1 SEC Form 4 filing on record, dated 29 October 2026. Most recent open-market trade: bought $9K of VRXA on 29 October 2026. Lifetime open-market purchases: $10K.
Recent transactions
2The latest 2 SEC Form 4 transactions reported by Marc Gruninger.
Trading pattern
InsiderAlpha's records for Marc Gruninger go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. The typical open-market purchase is $5K (2 buys totaling $10K). The largest single buy on record is $9K of VRXA in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Marc Gruninger files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Oliver Rolf Baumann - $75K in VRXA purchases and sales in the last 12 months
- Christoph Samuel Ziegler - $33K in VRXA purchases and sales in the last 12 months
- Christoph Rudiger Antz - $8K in VRXA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Marc Gruninger?
Marc Gruninger is a corporate insider, tracked as Director of Veraxa Biotech AG - Post de-SPAC (VRXA). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Marc Gruninger submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Marc Gruninger been buying or selling stock?
Recorded transactions: 2 open-market purchases ($10K) and 0 open-market sales across all tracked filings.